Results 281 to 290 of about 443,809 (299)

Do fourth-generation EGFR inhibitors showcase the future of kinase inhibitors?

Nature Reviews Drug Discovery, 2022
exaly  

Issues and progress with protein kinase inhibitors for cancer treatment

Nature Reviews Drug Discovery, 2003
Janet Dancey
exaly  

Long-term potentiation in the hippocampus is blocked by tyrosine kinase inhibitors

Nature, 1991
Thomas J O'dell, Eric R Kandel, Seth G Grant   +2 more
exaly  

Tyrosine Kinase Inhibitor

2013
openaire   +1 more source

Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective

Lancet Oncology, The, 2014
Roelof W F Van Leeuwen, Teun van Gelder, Ron H J Mathijssen   +2 more
exaly  

Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management

Ca-A Cancer Journal for Clinicians
Maxime Borgeaud, Jair Bar, Stephanie Saw
exaly  

Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study

Lancet, The, 2002
David Elashoff, Dieter Hoelzer, H Phillip Koeffler   +2 more
exaly  

Targeting Bruton's tyrosine kinase in B cell malignancies

Nature Reviews Cancer, 2014
Rudi W Hendriks, Saravanan Y Pillai
exaly  

Tyrosine kinase inhibitor special issue

Veterinary and Comparative Oncology, 2012
openaire   +2 more sources

A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors

Ca-A Cancer Journal for Clinicians
Chadi Hage Chehade, Georges Gebrael, Nicolas Sayegh   +2 more
exaly